用于5-ALA荧光引导切除的三LED手术放大镜设备的开发与验证
作者开发了一种三发光二极管(LED)头灯/放大镜设备用于可视化5-氨基乙酰丙酸(5-ALA)诱导的原卟啉IX荧光,并与BLUE400金标准进行对比。在26例恶性胶质瘤患者的240份活检样本中,以BLUE400为参考,新设备的灵敏度为100%、特异度为95%、准确率为95%,一致率为94.2%(95%CI 0.904-0.968),达到主要研究目标。
要点
- 新三LED放大镜设备在409nm和450nm光照强度与BLUE400相当,光斑均匀性高。
- 放大镜设备远端荧光强度较显微镜目镜高9.9倍。
- 240份样本中226份(94.2%,95%CI 0.904-0.968)荧光判断一致,达到主要目标。
核心结论
- 作者观察到光谱和光照强度方面仅有微小差异,放大镜设备可供外科医生使用的荧光强度高9.9倍,新系统与BLUE400的独立荧光感知在统计学上等效。
- 作者认为三LED放大镜设备对于偏好放大镜而非显微镜进行合适患者切除的外科医生是一种有用且安全的选择。
研究设计与样本
- 前瞻性随机盲法研究,比较三LED头灯/放大镜设备与BLUE400在恶性胶质瘤患者中的荧光评估。
- 纳入26例接受20 mg/kg体重5-ALA治疗的恶性胶质瘤患者,共240份活检样本。
- 样本由不同外科医生分别使用Kinevo显微镜和新型三LED放大镜设备立即轮流评估。
- 分析了7台三LED放大镜设备的光谱、光照强度、检测强度和光斑均匀性。
主要发现
- 409nm和450nm范围光照强度与BLUE400相当,光斑均匀性高。
- 放大镜设备远端测量的荧光强度较显微镜目镜高9.9倍。
- 以BLUE400结果为参考,新设备重现荧光发现的灵敏度为100%,特异度为95%,阳性预测值为98%,阴性预测值为100%,准确率为95%。
- 240份样本中226份一致(94.2%,95%CI 0.904-0.968),达到主要研究目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fluorescence-guided resections performed using 5-aminolevulinic acid (5-ALA) have been studied extensively using the BLUE400 system. The authors introduce a triple-light-emitting diode (LED) headlight/loupe device for visualizing fluorescence, and compare this to the BLUE400 gold standard in order to assure similar and not more or less sensitive protoporphyrin-IX visualization. METHODS: The authors defined the spectral requirements for a triple-LED headlight/loupe device for reproducing the xenon-based BLUE400 module. The system consisted of a white LED (normal surgery), a 409-nm LED for excitation, a 450-nm LED for background illumination, and appropriate observation filters. The prototype's excitation and emission spectra, illumination and detection intensities, and spot homogeneity were determined. The authors further performed a prospectively randomized and blinded study for fluorescence assessments of fresh, marginal, fluorescing and nonfluorescing tumor samples comparing the LED/loupe device with BLUE400 in patients with malignant glioma treated with 20 mg/kg body weight 5-ALA. Tumor samples were immediately assessed in turn, both with a Kinevo and with a novel triple-LED/loupe device by different surgeons. RESULTS: Seven triple-LED/loupe devices were analyzed. Illumination intensities in the 409- and 450-nm range were comparable to BLUE400, with high spot homogeneity. Fluorescence intensities measured distally to microscope oculars/loupes were 9.9-fold higher with the loupe device. For validation 26 patients with malignant gliomas with 240 biopsies were analyzed. With BLUE400 results as the reference, sensitivity for reproducing fluorescence findings was 100%, specificity was 95%, positive predictive value was 98%, negative predictive value was 100%, and accuracy was 95%. This study reached its primary aim, with agreement in 226 of 240 (94.2%, 95% CI 0.904-0.968). CONCLUSIONS: The authors observed only minor differences regarding spectra and illumination intensities during evaluation. Fluorescence intensities available to surgeons were 9.9-fold higher with the loupe device. Importantly, the independent perception of fluorescence achieved using the new system and BLUE400 was statistically equivalent. The authors believe the triple-LED/loupe device to be a useful and safe option for surgeons who prefer loupes to the microscope for resections in appropriate patients.
引用
- Suero Molina E, Hellwig SJ, Walke A, et al. Development and validation of a triple-LED surgical loupe device for fluorescence-guided resections with 5-ALA. J Neurosurg. 2021. PMID: 34972076. doi:10.3171/2021.10.JNS211911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。